Sangamo Deferred Long Term Liab from 2010 to 2024
| SGMO Stock | USD 2.35 0.47 16.67% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 6.3 M | Current Value 6.4 M | Quarterly Volatility 8.8 M |
Check Sangamo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sangamo Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 11.4 M, Total Revenue of 185 M or Other Operating Expenses of 472.7 M, as well as many indicators such as Price To Sales Ratio of 0.51, Dividend Yield of 0.0 or PTB Ratio of 1.09. Sangamo financial statements analysis is a perfect complement when working with Sangamo Therapeutics Valuation or Volatility modules.
Sangamo | Deferred Long Term Liab |
Latest Sangamo Therapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Sangamo Therapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Sangamo Therapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sangamo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Sangamo Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 7,900,322 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 86.25 | |
| Mean Deviation | 3,964,272 | |
| Median | 6,705,000 | |
| Standard Deviation | 6,814,141 | |
| Sample Variance | 46.4T | |
| Range | 29.2M | |
| R-Value | 0.18 | |
| Mean Square Error | 48.3T | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | 280,422 | |
| Total Sum of Squares | 650.1T |
Sangamo Deferred Long Term Liab History
About Sangamo Therapeutics Financial Statements
Sangamo Therapeutics investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Sangamo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 7.2 M | 9.3 M |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sangamo Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | LLY | Eli Lilly | PairCorr |
| 0.76 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.67 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Sangamo Therapeutics Correlation against competitors. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.